全文获取类型
收费全文 | 232637篇 |
免费 | 16430篇 |
国内免费 | 7648篇 |
专业分类
耳鼻咽喉 | 3056篇 |
儿科学 | 3464篇 |
妇产科学 | 2624篇 |
基础医学 | 29910篇 |
口腔科学 | 4915篇 |
临床医学 | 23467篇 |
内科学 | 37562篇 |
皮肤病学 | 5121篇 |
神经病学 | 15396篇 |
特种医学 | 11636篇 |
外国民族医学 | 25篇 |
外科学 | 28916篇 |
综合类 | 21580篇 |
现状与发展 | 30篇 |
一般理论 | 35篇 |
预防医学 | 15919篇 |
眼科学 | 5131篇 |
药学 | 22167篇 |
109篇 | |
中国医学 | 7648篇 |
肿瘤学 | 18004篇 |
出版年
2024年 | 398篇 |
2023年 | 2037篇 |
2022年 | 5610篇 |
2021年 | 8569篇 |
2020年 | 5307篇 |
2019年 | 5509篇 |
2018年 | 6421篇 |
2017年 | 5964篇 |
2016年 | 6789篇 |
2015年 | 9872篇 |
2014年 | 12167篇 |
2013年 | 13517篇 |
2012年 | 20225篇 |
2011年 | 20404篇 |
2010年 | 13821篇 |
2009年 | 11851篇 |
2008年 | 15068篇 |
2007年 | 14678篇 |
2006年 | 13224篇 |
2005年 | 12054篇 |
2004年 | 9752篇 |
2003年 | 8833篇 |
2002年 | 7578篇 |
2001年 | 5280篇 |
2000年 | 4504篇 |
1999年 | 3233篇 |
1998年 | 1625篇 |
1997年 | 1401篇 |
1996年 | 997篇 |
1995年 | 891篇 |
1994年 | 761篇 |
1993年 | 569篇 |
1992年 | 950篇 |
1991年 | 866篇 |
1990年 | 762篇 |
1989年 | 656篇 |
1988年 | 544篇 |
1987年 | 534篇 |
1986年 | 403篇 |
1985年 | 405篇 |
1984年 | 308篇 |
1983年 | 216篇 |
1982年 | 160篇 |
1981年 | 189篇 |
1980年 | 152篇 |
1979年 | 235篇 |
1978年 | 181篇 |
1976年 | 139篇 |
1975年 | 136篇 |
1974年 | 152篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
51.
52.
Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. 总被引:1,自引:0,他引:1
Beta-adrenergic receptor density on T cells from healthy humans is greatest on suppressor cells (CD8+, CD28-) and the effect of catecholamines, secreted by the sympathetic nervous system, predominates on this subset. The sympathetic skin response, a measure of sympathetic nervous system function, is absent in most patients with chronic progressive multiple sclerosis (MS). We measured beta-adrenergic receptor density on suppressor cells, cytotoxic cells, and monocytes from patients with chronic progressive MS and healthy control subjects. Control receptor density on suppressor cells was 2.8 +/- 0.3 fmol/10(6) cells versus a density of 5.1 +/- 0.7 fmol/10(6) cells for patients. Cytotoxic cell (CD8+, CD28+) receptor density was 1.4 +/- 0.4 fmol/10(6) cells in control subjects and 0.9 +/- 0.3 fmol/10(6) cells in the patients. Monocytes displayed beta-adrenergic receptor densities of 2.6 +/- 0.4 fmol/10(6) cells in normal individuals and 2.7 +/- 0.4 fmol/10(6) cells in the patient group. CD8 lymphocyte beta-adrenergic receptor densities in patients with relapsing-remitting and those with stable MS were not different from control values, yet were significantly less than the values for patients with chronic progressive MS. We find that mononuclear cells from healthy control subjects and patients with chronic progressive MS proliferate in response to 200 units/ml of recombinant human interleukin-2 (IL-2) similarly. However, IL-2 treatment increased beta-adrenergic receptor density on normal mononuclear cells, but failed to increase it on mononuclear cells from patients with chronic progressive MS.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
53.
54.
Chang Y Jung Hyo S Choi Jin S Ju Hyo S Park Tae G Kwon Yong C Bae Dong K Ahn 《The journal of pain》2006,7(10):747-756
The present study investigated the role of central metabotropic glutamate receptors (mGluRs) in interleukin-1beta (IL-1beta)-induced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Experiments were carried out on male Sprague-Dawley rats weighing 230 to 280 g. After administration of 0.01, 0.1, 1, or 10 pg of IL-1beta into a subcutaneous area of the vibrissa pad, we examined the withdrawal behavioral responses produced by 10 successive trials of an air-puff ramp pressure applied ipsilaterally or contralaterally to the IL-1beta injection site. Subcutaneous injection of IL-1beta produced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Intracisternal administration of CPCCOEt, a mGluR1 antagonist, or MPEP, a mGluR5 antagonist, reduced IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. Intracisternal administration of APDC, a group II mGluR agonist, or L-AP4, a group III mGluR agonist, reduced both IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. The antiallodynic effect, induced by APDC or L-AP4, was blocked by intracisternal pretreatment with LY341495, a group II mGluR antagonist, or CPPG, a group III mGluR antagonist. These results suggest that groups I, II, and III mGluRs differentially modulated IL-1beta-induced mechanical allodynia, as well as mirror-image mechanical allodynia, in the orofacial area. PERSPECTIVE: Central group I mGluR antagonists and groups II and III mGluR agonists modulate IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Therefore, the central application of group I mGluR antagonists or groups II and III mGluR agonists might be of therapeutic value in treating pain disorder. 相似文献
55.
目的应用显微手术夹闭、血管内栓塞和栓塞后手术夹闭3种治疗方法,探讨治疗颅内破裂动脉瘤的安全有效方案。方法显微手术瘤颈夹闭30个动脉瘤,栓塞34个动脉瘤,栓塞后夹闭15个动脉瘤。结果夹闭组30个完全夹闭,无复发,死亡率6%(2/30)。栓塞组完全闭塞率70.6%(24/34),复发率17.6%(6/34),死亡率11.8%(4/34)。栓塞后手术组15个完全夹闭,无复发,死亡率6.7%(1/15)。治疗结束用GOS评价,1个月后3组良好率分别为80.0%、79.4%和80.0%;半年后良好率分别为90.0%、88.2%和86.7%。结论显微手术瘤颈夹闭术仍然是治疗破裂动脉瘤的有效方法,具有1次治疗彻底和复发率低的优势,并可作为栓塞失败的补救手段。 相似文献
56.
57.
58.
59.
60.
Diseases like rotavirus afflict both upper- and lower-income countries, but most serious illnesses and deaths occur among the latter. It is a vital public health issue that vaccines for these types of global diseases can recover research and development (R&D) costs from high-priced markets quickly so that manufacturers can offer affordable prices to lower-income nations. Cost recovery depends on how high R&D costs are, and this study attempts to replace high, unverified estimates with lower, more verifiable estimates for two new vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline or GSK), based on detailed searches of public information and follow-up interviews with senior informants. We also offer a new perspective on “cost of capital” as a claim for recovery from public bodies. Our estimates suggest that companies can recover all fixed costs quickly from affluent markets and thus can offer these vaccines to lower-income countries at prices they can afford. Better vaccines are a shared project between companies and public health agencies; greater transparency and consistency in reporting of R&D costs is needed so that fair prices can be established. 相似文献